psychedelics investing MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics
psychedelics investing MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161 million USD to Support Drug Development Pipeline and Creation of Psychedelic Medicine Tech Platform
psychedelics investing MindMed Announces the Addition of Stanford University Neuroscientist as Chair of the Scientific Advisory Board
psychedelics investing MindMed Increases Cash on Hand to CAD $205.2m , Closes Financing of CAD $19.5m
psychedelics investing MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company
psychedelics investing MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company
psychedelics investing MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds
psychedelics investing MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics
psychedelics investing MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD
